Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

fect of P-gp Inducers & Inhibitors on Dabigatran Exposure
The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are major independent factors in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS
In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in higher rates of major GI bleeds and any GI bleeds compared to warfarin. In patients >75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated
In the pivotal trial, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA (0.7 per 100 patient-years for 150 mg dose) than in those who received warfarin (0.6).

Click

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at ... describe in a case report the first successful use ... a 13- year-old boy with failing Fontan circulation to ... he was 3 years old, the patient received a ... as functional single ventricle. "The Fontan operation is the ...
(Date:9/16/2014)... Research and Markets has ... Devices Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth ... laparoscopic devices. The report provides a ... applications and industry chain structure. The laparoscopic devices ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Global Laparoscopy Devices Industry Report 2014 2
... 23, 2011 The U.S. Food and Drug Administration ... active ulcerative colitis (UC) in children older than 6 ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... induces and maintains clinical remission in these patients. ...
... ANN ARBOR, Mich., Sept. 23, 2011 Adapting adult medical ... often problematic practice across U.S. hospitals. At the ... and researchers who care for children have been leading the ... test medical devices and curb problems that come from using ...
Cached Medicine Technology:FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 2FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 2University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 4
(Date:9/16/2014)... Centre, NY (PRWEB) September 16, 2014 ... product manufactured by Johnson & Johnson subsidiary Ethicon concluded ... of plaintiff Jo Huskey and awarding her $3.27 million ... According to the Reuters report, “jurors found Ethicon liable ... and their doctors that users were at risk from ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
(Date:9/16/2014)... September 16, 2014 Duke’s Chowder House ... Rebls and Gratafy for a fun evening ... hub is firmly cemented. With the growth of companies in these ... for people who work in tech and at startups to connect ... Gratafy are happy to host events for their peers to meet ...
(Date:9/16/2014)... Treatment with endocrine therapy and radiation therapy as ... of care for women with hormone-receptor positive (HR+) ... at Fox Chase Cancer Center, however, shows that ... populations with the disease. , The results, ... Society for Radiation Oncology,s 56th Annual Meeting on ...
(Date:9/16/2014)... 16, 2014 This year’s theme is ... Sustainable company Glen Mills, Pennsylvania, September 15, 2014- Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... who don,t metabolize drug well, , FRIDAY, March 12 (HealthDay ... "black box" warning on its label, alerting patients and doctors ... officials said Friday. , Patients with a certain genetic variation ... puts them at risk for heart attack and stroke, the ...
... with a known sex offender is beginning to settle in as a dark, dark corner of the landscape of life. Slowly we are taking up our routines again, changed by ... ... ... ...
... released the following statement.  , ... , , ... ... "We applaud the steps taken by the Congressional Black Caucus and the White House to meet to discuss the ...
... , ... , ... ... ST. LOUIS , March 12 More than 200 Teamsters and religious leaders held a rally and prayer vigil at Ascension ...
... Award Presented to Joel A. Gingras, Jr. Memorial Fund , ... , , ... ... CHICAGO , March 12 The American Brain Tumor Association (ABTA) presented its first ...
... profitable and industry-leading corporation, LIMU, based in Florida , today announced a brand transformation for 2010.   With ... upcoming international convention March 19 – 20, 2010 in Dallas, Texas . , ... ... , ...
Cached Medicine News:Health News:Plavix Less Effective in Some Patients 2Health News:Plavix Less Effective in Some Patients 3Health News:TypeAMom.net on Keeping Daughters Safe From Predators 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 3Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 4Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 5Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 6Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 7Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 8Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 2Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 3Health News:LIMU Accelerates Growth Era With Brand Transformation 2Health News:LIMU Accelerates Growth Era With Brand Transformation 3
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: